Last reviewed · How we verify
NCT07321288
Machine Learning-Based Prediction of Insulin Resistance in Psoriasis Patients Emphasizing Interpretability
trial in Psoriasis in 1,265 participants. Participants enrolled and being followed up; not accepting new ones.
1 September 2026
Quick facts
| Lead sponsor | Chinese PLA General Hospital |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 1,265 |
| Start date | 1 September 2025 |
| Primary completion | 1 September 2026 |
| Estimated completion | 1 September 2026 |
| Sites | 1 location across China |
Conditions studied
- Psoriasis — all drugs for Psoriasis →
- Insulin Resistance — all drugs for Insulin Resistance →
Sponsor
Chinese PLA General Hospital
Who can join
18 and older, any sex, with Psoriasis or Insulin Resistance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Psoriasis is a long-term inflammatory skin disease that can affect overall health. People with psoriasis have a higher risk of developing insulin resistance, a condition in which the body does not respond properly to insulin. Insulin resistance can increase the risk of diabetes, heart disease, and other serious health problems. Because insulin resistance often develops without clear symptoms, many patients are not diagnosed early. The purpose of this study is to identify which patients with psoriasis are more likely to develop insulin resistance and to create a tool that can help doctors estimate this risk for individual patients. The study will use existing medical records from two medical centers. Researchers will analyze information such as age, body weight, psoriasis severity, blood test results, other medical conditions, and medication history. Machine learning methods will be used to analyze these data and build a prediction model. The model will be designed to be easy to understand, so doctors can see which factors contribute most to insulin resistance risk. This study does not involve any new treatments or procedures. All patient information will be anonymized to protect privacy. The results may help doctors identify high-risk patients earlier and support timely monitoring and preventive care.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07321288
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Psoriasis
Currently open trials in the same condition.
- NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
- NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
- NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
- NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
- NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting
Other Chinese PLA General Hospital trials
Trials by the same sponsor.
- NCT07294755 — The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery · NA · not yet recruiting
- NCT07536607 — Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients · not yet recruiting
- NCT07489157 — Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy · NA · not yet recruiting
- NCT07494981 — Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations · not yet recruiting
- NCT07496008 — Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07321288 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese PLA General Hospital
- Last refreshed: 7 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07321288.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing